Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: ganciclovir

« Back to Dashboard
Ganciclovir is the generic ingredient in five branded drugs marketed by Roche Palo, Ranbaxy Labs Ltd, Bausch And Lomb, Fresenius Kabi Usa, Luitpold, and Eurohlth Intl Sarl, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for ganciclovir. One supplier is listed for this compound.

Summary for Generic Name: ganciclovir

Tradenames:5
Patents:0
Applicants:6
NDAs:8
Drug Master File Entries: see list22
Suppliers / Packaging: see list2
Therapeutic Class:Antivirals

Clinical Trials for: ganciclovir

Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis
Status: Completed Condition: Cytomegalovirus Anterior Segment Infection; Anterior Uveitis; Endotheliitis

Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
Status: Not yet recruiting Condition: Conjunctivitis; Adenovirus.

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
Status: Terminated Condition: Allogeneic Stem Cell Transplantation

Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
Status: Completed Condition: Infection in Solid Organ Transplant Recipients

Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis
Status: Completed Condition: Conjunctivitis, Viral; Adenoviridae Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
VITRASERT
ganciclovir
IMPLANT;IMPLANTATION020569-001Mar 4, 1996DISCNNo<disabled><disabled>
Roche Palo
CYTOVENE
ganciclovir
CAPSULE;ORAL020460-002Dec 12, 1997DISCNNo<disabled><disabled>
Roche Palo
CYTOVENE
ganciclovir sodium
INJECTABLE;INJECTION019661-001Jun 23, 1989RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ganciclovir

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche Palo
CYTOVENE
ganciclovir
CAPSULE;ORAL020460-001Dec 22, 19944,355,032<disabled>
Roche Palo
CYTOVENE
ganciclovir
CAPSULE;ORAL020460-002Dec 12, 19974,642,346<disabled>
Roche Palo
CYTOVENE
ganciclovir
CAPSULE;ORAL020460-002Dec 12, 19974,507,305<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc